AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25199409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RAP)
Number of subjects: 3084
Study 24319686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (oral administration)
Number of subjects: 41
Study 24319686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study 20958228 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (L-Arg) supplementation
Number of subjects: 80
Study 20958228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone (0.15 mg/kg)
Number of subjects: 133
Study 18509120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 17191025 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea-supplemented diet
Number of subjects: 47
Study 17191025 — intervention group
Group type: COMPARATOR
Intervention: Wheat-supplemented diet
Number of subjects: 47
Study 12709698 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection with immediate bleeding
Number of subjects: 477
Study 12709698 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection without immediate bleeding
Number of subjects: 477
Study 11232191 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific vaccines for hepatitis A and B
Number of subjects: 0
Study 11232191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive combination therapy for chronic hepatitis B and C
Number of subjects: 0
Study 9081951 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml/kg (1:200,000) epinephrine combined with 0.25% bupivacaine (n = 33)
Number of subjects: 103
Study 9081951 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine (n = 36)
Number of subjects: 103
Study 9081951 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group, n = 34)
Number of subjects: 103
Study 9081951 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment methods
Number of subjects: 103
Study 1313098 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg orally four times daily for 5 days)
Number of subjects: 62
Study 1313098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2860992 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin, 100 mg) given twice daily for 6 weeks
Number of subjects: 8
Study 2860992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30848938 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week multimodal rehabilitation program (12 intervention sessions and daily home ankle strengthening and stretching)
Number of subjects: 20
Study 30848938 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week multimodal rehabilitation program
Number of subjects: 20
Study 29547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention intervention
Number of subjects: 24
Study 29547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective agency among sex workers
Number of subjects: 24
Study 26845264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + adjunctive personalized treatment (APT)
Number of subjects: 482
Study 26845264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine + adjunctive personalized treatment (APT)
Number of subjects: 482
Study 26845264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482
Study 26845264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482
Study 24158407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 14
Study 24158407 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PAS)
Number of subjects: 14
Study 22818869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (50 mg/d)
Number of subjects: 85
Study 22818869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 22818869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine (1 g/d)
Number of subjects: 85
Study 22818869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine (1 g/d)
Number of subjects: 85
Study 22818869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine (1 g/d) + Vitamin B(6) (50 mg/d)
Number of subjects: 85
Study 20631020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU ergocalciferol, 4 doses over 1 year)
Number of subjects: 69
Study 20631020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 69
Study 20631020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 69
Study 17908660 — intervention group
Group type: EXPERIMENTAL
Intervention: PRONE (n = 11)
Number of subjects: 22
Study 17908660 — intervention group
Group type: COMPARATOR
Intervention: SUPINE (n = 11)
Number of subjects: 22
Study 12574809 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran followed by oral ximelagatran (3 mg subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg oral ximelagatran twice-daily for 8 to 11 days)
Number of subjects: 2788
Study 12574809 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg subcutaneous enoxaparin once-daily, started 12 h preoperatively)
Number of subjects: 2788
Study 12574809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2788
Study 10711583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 65
Study 10711583 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study 8941404 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 73
Study 8941404 — intervention group
Group type: COMPARATOR
Intervention: Teniposide/cisplatin
Number of subjects: 73
Study 1587940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% solution of povidon iodine (Betadine)
Number of subjects: 334
Study 1587940 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 334
Study 3907910 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 20 mg intravenously
Number of subjects: 20
Study 3907910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no verapamil)
Number of subjects: 20
Study 30773140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional micronutrients
Number of subjects: 875
Study 30773140 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutritional supplement without additional micronutrients
Number of subjects: 875
Study 30773140 — intervention group
Group type: COMPARATOR
Intervention: Iron-folate (standard care)
Number of subjects: 875
Study 30773140 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients
Number of subjects: 875
Study 30773140 — intervention group
Group type: COMPARATOR
Intervention: Protein energy
Number of subjects: 875
Study 30773140 — intervention group
Group type: COMPARATOR
Intervention: Protein energy + multiple micronutrients
Number of subjects: 875
Study 28633996 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa (DOPA)
Number of subjects: 10
Study 28633996 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH)
Number of subjects: 10
Study 28633996 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (MEPH)
Number of subjects: 10
Study 28633996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 10
Study 26116695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg)
Number of subjects: 15
Study 26116695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23800140 — intervention group
Group type: EXPERIMENTAL
Intervention: qHBsAg index
Number of subjects: 197
Study 23800140 — intervention group
Group type: EXPERIMENTAL
Intervention: GqHBsR
Number of subjects: 197
Study 23800140 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 197
Study 23800140 — intervention group
Group type: EXPERIMENTAL
Intervention: aspartate aminotransferase to platelet ratio index
Number of subjects: 197
Study 21335058 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital TMS during non-REM sleep
Number of subjects: 0
Study 21335058 — intervention group
Group type: COMPARATOR
Intervention: Occipital TMS during wakefulness
Number of subjects: 0
Study 20003665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry drink (500 ml twice per day)
Number of subjects: 12
Study 20003665 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 17013602 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite porous coating
Number of subjects: 100
Study 17013602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coating)
Number of subjects: 100
Study 14520337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 6
Study 14520337 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 6
Study 11307640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0
Study 11307640 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study 8769051 — intervention group
Group type: EXPERIMENTAL
Intervention: GR3219 80 mg twice daily
Number of subjects: 59
Study 8769051 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg daily
Number of subjects: 59
Study 1573046 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 94
Study 1573046 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 6 mg
Number of subjects: 94
Study 1573046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3881905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine in cold hyperkalemic cardioplegic solution
Number of subjects: 0
Study 3881905 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study 31518155 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 127
Study 31518155 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 127
Study 29368365 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlorotannin supplement (500 mg/day)
Number of subjects: 24
Study 26850983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 μg every 4 hours)
Number of subjects: 1859
Study 26850983 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter (30 mL transcervical)
Number of subjects: 1859
Study 26850983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 1859
Study 26850983 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 1859
Study 24550378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin prophylaxis
Number of subjects: 222
Study 24550378 — intervention group
Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 222
Study 24550378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin preemptive therapy
Number of subjects: 222
Study 24550378 — intervention group
Group type: COMPARATOR
Intervention: Placebo preemptive therapy
Number of subjects: 222
Study 22099607 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (escitalopram)
Number of subjects: 5
Study 22099607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 20819537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) administered continuously for at least 12 hours (group L)
Number of subjects: 16
Study 20819537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) administered for 1 hour (group S)
Number of subjects: 16
Study 20819537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) (both groups)
Number of subjects: 16
Study 18424479 — intervention group
Group type: COMPARATOR
Intervention: M‐GA (mitoxantrone followed by glatiramer acetate)
Number of subjects: 40
Study 18424479 — intervention group
Group type: COMPARATOR
Intervention: GA (glatiramer acetate alone)
Number of subjects: 40
Study 16409566 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan, 300 mg
Number of subjects: 30
Study 16409566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14978984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg (intravenous) 8 hourly
Number of subjects: 52
Study 14978984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g 8 hourly through a Ryle's tube
Number of subjects: 52
Study 14978984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 52
Study 11201591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 200
Study 11201591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium scintigraphy
Number of subjects: 200
Study 11201591 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical suspicion of coronary artery disease
Number of subjects: 200
Study 8698278 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/Large plaque (n = 96)
Number of subjects: 181
Study 8698278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum intima-media thickness of the femoral artery
Number of subjects: 181
Study 8698278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical atherosclerosis
Number of subjects: 181
Study 8698278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen, von Willebrand factor and thrombin/antithrombin complex
Number of subjects: 181
Study 1538036 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-wheeled walker
Number of subjects: 15
Study 1538036 — intervention group
Group type: COMPARATOR
Intervention: 2-wheeled walker
Number of subjects: 15
Study 31747864 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four 5-minute cycles
Number of subjects: 60
Study 31747864 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 31747864 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 60
Study 28520861 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in France
Number of subjects: 1800
Study 28520861 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in Hungary
Number of subjects: 1800
Study 28520861 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting in the UK
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia usage
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Bilateral internal mammary artery usage
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Off-pump procedures
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Implanted stents in percutaneous coronary intervention
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Total stent length in percutaneous coronary intervention
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Acetylsalicylic acid
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Thienopyridine
Number of subjects: 1800
Study 28520861 — intervention group
Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Statins
Number of subjects: 1800
Study 25769902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropomyosin and sarcoplasmic calcium-binding proteins
Number of subjects: 86
Study 25769902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoplasmic calcium-binding protein positive test
Number of subjects: 86
Study 25769902 — intervention group
Group type: COMPARATOR
Intervention: Arginine kinase and hemocyanin
Number of subjects: 86
Study 25769902 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosin light chain testing
Number of subjects: 86
Study 25769902 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IgE to allergens and some of their epitopes
Number of subjects: 86
Study 23698545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 92
Study 23698545 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 92
Study 21301783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg/kg methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim)
Number of subjects: 78
Study 21226428 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg (1.5 ml) hyperbaric levobupivacaine 0.5%
Number of subjects: 60
Study 21226428 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg (4 ml) hypobaric levobupivacaine 0.1875%
Number of subjects: 60
Study 17381974 — intervention group
Group type: EXPERIMENTAL
Intervention: High unsalted cashew nut diet
Number of subjects: 64
Study 17381974 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no nuts)
Number of subjects: 64
Study 17381974 — intervention group
Group type: EXPERIMENTAL
Intervention: High walnut diet
Number of subjects: 64
Study 15705722 — intervention group
Group type: EXPERIMENTAL
Intervention: BREx group (resistive exercise)
Number of subjects: 18
Study 15705722 — intervention group
Group type: COMPARATOR
Intervention: BR group (bed rest only)
Number of subjects: 18
Study 12913399 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab/rPA (n = 5)
Number of subjects: 15
Study 12913399 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban/TNK‐tPA (n = 5)
Number of subjects: 15
Study 12913399 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 9481529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Number of subjects: 22
Study 9481529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Number of subjects: 22
Study 8570043 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 150 mgI/ml
Number of subjects: 86
Study 8570043 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 140 mgI/ml
Number of subjects: 86
Study 2096212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg orally twice daily for 3.5 days
Number of subjects: 24
Study 81925 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.1 mg/kg intravenously followed by 320 mg orally over 27 h
Number of subjects: 20
Study 81925 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 subjects)
Number of subjects: 20
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 0.49 ng/mL or less
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 0.50-0.99 ng/mL
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 1.00-1.99 ng/mL
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 2.00-2.99 ng/mL
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 3.00-3.99 ng/mL
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 4.00 ng/mL and greater
Number of subjects: 10968
Study 31940039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 2.00 ng/mL or higher
Number of subjects: 10968
Study 31361516 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep It Up! (KIU!) online intervention
Number of subjects: 0
Study 28434547 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-dose corticosteroid (SDC) regimen: 2 mg/kg methylprednisolone perioperatively, followed by hydrocortisone infusion (0.2 mg/kg/h) for 5 days
Number of subjects: 40
Study 28434547 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-dose corticosteroid (SDC) regimen
Number of subjects: 40
Study 28434547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25585082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical diltiazem ointment (for 6 weeks) and botulinum toxin A injection (once)
Number of subjects: 99
Study 25585082 — intervention group
Group type: COMPARATOR
Intervention: Partial lateral internal sphincterotomy
Number of subjects: 99
Study 23507282 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg solithromycin orally on day 1, followed by 400 mg orally daily on days 2 to 5
Number of subjects: 132
Study 23507282 — intervention group
Group type: COMPARATOR
Intervention: 750 mg levofloxacin orally daily on days 1 to 5
Number of subjects: 132
Study 23507282 — intervention group
Group type: COMPARATOR
Intervention: levofloxacin
Number of subjects: 132
Study 23507282 — intervention group
Group type: EXPERIMENTAL
Intervention: solithromycin
Number of subjects: 132
Study 21669583 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables before carbohydrate (VBC)
Number of subjects: 101
Study 21669583 — intervention group
Group type: COMPARATOR
Intervention: Exchange-based meal plan (EXB)
Number of subjects: 101
Study 19452377 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)
Number of subjects: 0
Study 19452377 — intervention group
Group type: COMPARATOR
Intervention: SNRI (venlafaxine)
Number of subjects: 0
Study 17164458 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 16958
Study 15120545 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory repetition priming
Number of subjects: 0
Study 15120545 — intervention group
Group type: EXPERIMENTAL
Intervention: Word stem completion priming
Number of subjects: 0
Study 15120545 — intervention group
Group type: COMPARATOR
Intervention: Lexical decision priming measures
Number of subjects: 0
Study 11146900 — intervention group
Group type: EXPERIMENTAL
Intervention: Propinox 10 mg
Number of subjects: 400